



# **70<sup>TH</sup> ESCVS CONGRESS & 7<sup>TH</sup> IMAD MEETING**

**20 | 23 JUNE 2022**

**Liège | Théâtre de Liège | Belgium**

**[www.escvs2022.com](http://www.escvs2022.com)**



**70th ESCVS**  
International congress of the European Society  
for Cardiovascular and Endovascular Surgery



**7<sup>th</sup> IMAD meeting**



**20 I 23 JUNE 2022**


Liège | Théâtre de Liège | Belgium  
[www.escvs2022.com](http://www.escvs2022.com)

# PDA/RVOT stenting neonatally prior to surgical repair in TOF

Cools Bjorn


**No disclosures**

## Newborn Fallot




# Primary repair in neonates


| Study         | Years   | Number of patients | Early mortality |
|---------------|---------|--------------------|-----------------|
| STS           | 2003-07 | 178                | 7.8%            |
| PHIS          | 2004-15 | 1032               | 6.0%            |
| KIDS          | 2003-10 | 537                | 10.5%           |
| CCRC (<2.5kg) | 2005-17 | 122                | 15%             |




- Transannular patch >80%
- Morbidity ↑
- ICU stay ↑








**CENTRAL ILLUSTRATION: Comparison of Management Strategies From 572 Neonates With Symptomatic Tetralogy of Fallot: Results From the Congenital Cardiac Research Collaborative**






Goldstein, B.H. et al. J Am Coll Cardiol. 2021;77(8):1093-106.






# RVOT stent >< PDA stent











# PA growth after RVOT stent










# PA growth RVOT stent vs mBTS



# TOF with Pulmonary Atresia



# Removal of the RVOT stent



- 86% TAP
- 9/15 small part of stent was left in situ
- RVOT stenting does not alter vascular cytoarchitecture

# Conclusions

Cyanotic TOF



< 3 kg

Severe comorbidities

Small branch PA



Initial palliation



RVOT stent > PDA stent